Literature DB >> 9549813

Ensuring the quality of quality of life data: the Southwest Oncology Group experience.

C M Moinpour1, L C Lovato.   

Abstract

The Southwest Oncology Group (SWOG) has successfully included quality of life (QOL) questionnaires in selected oncology treatment trials. Extensive quality control procedures have been necessary for obtaining and maintaining good questionnaire submission rates. Since the first QOL study was activated in SWOG in 1990, the Group has found it increasingly necessary to incorporate centralized monitoring of the QOL assessment schedule. Successful quality control strategies are presented. Current submission rates for five SWOG phase III treatment trials (both open and closed) and one chemoprevention trial are presented for those scheduled QOL assessments for which we have follow-up data. Reasons for missing QOL questionnaires and the extent of missing data within submitted QOL questionnaires are described for two different disease contexts: a trial for patients with advanced stage disease, and a trial for patients with earlier stage disease.

Entities:  

Mesh:

Year:  1998        PMID: 9549813     DOI: 10.1002/(sici)1097-0258(19980315/15)17:5/7<641::aid-sim811>3.0.co;2-w

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

Review 1.  Patient-Clinician choice in palliation of metastatic prostate cancer.

Authors:  A V Kaisary
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

2.  Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.

Authors:  Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley
Journal:  J Natl Cancer Inst       Date:  2011-12-07       Impact factor: 13.506

3.  Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial.

Authors:  C M Moinpour; B Lyons; P K Grevstad; L C Lovato; J Crowley; K Czaplicki; Z M Buckner; P A Ganz; K Kelly; D R Gandara
Journal:  Qual Life Res       Date:  2002-03       Impact factor: 4.147

4.  Outcomes research in cancer clinical trial cooperative groups: the RTOG model.

Authors:  D W Bruner; B Movsas; A Konski; M Roach; M Bondy; C Scarintino; C Scott; W Curran
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

5.  Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma.

Authors:  M Walker; J Brown; K Brown; A Gregor; I R Whittle; R Grant
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

6.  Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers.

Authors:  Melanie Calvert; Derek Kyte; Helen Duffy; Adrian Gheorghe; Rebecca Mercieca-Bebber; Jonathan Ives; Heather Draper; Michael Brundage; Jane Blazeby; Madeleine King
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

7.  Health Care Professionals' Evaluation of Quality of Life Issues in Patients With Brain Metastases.

Authors:  Natalie Lauzon; Gillian Bedard; Liying Zhang; Arjun Sahgal; Liang Zeng; Kaitlin Koo; Edward Chow
Journal:  World J Oncol       Date:  2013-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.